BDTX - CIK 0001701541
The table below shows Black Diamond Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $29.61M | -$62.30M | -$66.72M | -$85.08M | -$100.15M | -$52.15M |
| Capital expenditure | - | $0.00 | $33.00K | $192.00K | $2.71M | $142.00K |
| Investing cash flow | -$44.91M | $16.97M | $16.35M | $53.37M | $130.61M | -$281.69M |
| Dividends paid | - | - | - | - | - |
Black Diamond Therapeutics, Inc. reported operating cash flow of $29.61M for fiscal year 2025. That is up 147.5% from -$62.30M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow grew from -$8.45M (FY 2018) to $29.61M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | -$146.00K | $25.55M | $71.93M | $177.00K | $729.00K | $214.94M |